Can a Dual-Targeting drug shrink Hard-to-Treat tumors?

NCT ID NCT07772934

NEW Not yet recruiting Disease control Sponsor: VelaVigo Bio Inc Source: ClinicalTrials.gov ↗

First seen Aug 19, 2026 · Last updated Aug 19, 2026

Summary

This trial tests VBC117, an investigational drug designed to attach to two proteins found on tumor cells and deliver a toxic payload directly to them. The study enrolls adults with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to find the safest and most effective dose and to see whether VBC117 can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VBC117, an experimental bispecific antibody-drug conjugate targeting EGFR and CDH17
What this could lead to: If successful, VBC117 could offer a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early-phase, first-in-human trial, so safety and effectiveness are not yet established. The drug may cause side effects or may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Cancer Care Wollongong

Wollongong, New South Wales, 2500, Australia
First Hospital of Shanxi Medical University

Taiyuan, Shanxi, 030001, China
Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Liaoning Cancer Hospital & Institute

Shengyang, Liaoning, 110042, China
Macquarie University

Randwick, New South Wales, 2031, Australia
Peninsula and South Eastern Haematology and Oncology Group

Frankston, Victoria, 3199, Australia
Scientia Clinical Research

Randwick, New South Wales, 2031, Australia
Shanghai East Hospital

Shanghai, Shanghai Municipality, 200120, China
Shanghai GoBroad Cancer Hospital

Shanghai, Shanghai Municipality, 200120, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450052, China
The Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330006, China
The Second Affiliated Hospital of Zhejiang University School of Medicine

Zhejiang, Hangzhou, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.